Natus Medical Inc. (NASDAQ:BABY) issued an update on its fourth quarter earnings guidance on Wednesday morning. The company provided earnings per share guidance of $0.52-0.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.48. The company issued revenue guidance of $107-109 million, compared to the consensus revenue estimate of $104.62 million.
Natus Medical Inc. (NASDAQ:BABY) opened at 39.70 on Wednesday. The company’s 50-day moving average price is $41.06 and its 200 day moving average price is $37.00. The firm has a market capitalization of $1.29 billion, a PE ratio of 34.22 and a beta of 0.78. Natus Medical Inc. has a 1-year low of $29.54 and a 1-year high of $51.05.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings results on Wednesday, October 19th. The company reported $0.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.05. Natus Medical had a return on equity of 13.82% and a net margin of 10.20%. The company had revenue of $90.90 million for the quarter, compared to analyst estimates of $89.94 million. During the same quarter in the prior year, the company posted $0.39 EPS. The business’s revenue for the quarter was down 3.9% compared to the same quarter last year. On average, equities analysts anticipate that Natus Medical Inc. will post $1.55 EPS for the current year.
Several research analysts recently weighed in on the company. Raymond James Financial Inc. raised Natus Medical from a market perform rating to an outperform rating and set a $46.00 target price on the stock in a research report on Tuesday, September 13th. Benchmark Co. assumed coverage on Natus Medical in a report on Tuesday, October 4th. They issued a buy rating and a $55.00 price target for the company. Finally, Zacks Investment Research upgraded Natus Medical from a hold rating to a buy rating and set a $44.00 target price for the company in a research note on Thursday, July 7th.
In other Natus Medical news, insider James B. Hawkins purchased 10,000 shares of the business’s stock in a transaction dated Wednesday, September 28th. The shares were bought at an average price of $38.48 per share, with a total value of $384,800.00. Following the completion of the acquisition, the insider now owns 459,725 shares in the company, valued at approximately $17,690,218. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.80% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its position in Natus Medical by 36.0% in the second quarter. BlackRock Inc. now owns 3,096 shares of the company’s stock worth $117,000 after buying an additional 820 shares in the last quarter. Invictus RG raised its position in Natus Medical by 8.7% in the second quarter. Invictus RG now owns 4,200 shares of the company’s stock valued at $159,000 after buying an additional 336 shares during the period. Trexquant Investment LP acquired a new position in Natus Medical during the second quarter valued at about $302,000. Clinton Group Inc. raised its position in Natus Medical by 0.7% in the second quarter. Clinton Group Inc. now owns 8,614 shares of the company’s stock valued at $326,000 after buying an additional 64 shares during the period. Finally, Raymond James & Associates raised its position in Natus Medical by 2.5% in the second quarter. Raymond James & Associates now owns 14,900 shares of the company’s stock valued at $563,000 after buying an additional 367 shares during the period. 88.00% of the stock is currently owned by institutional investors.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.